Companion diagnostic for cutaneous and uveal melanoma
Prognostic biomarker for cutaneous and uveal melanoma
Combination therapy for metastatic melanoma
Inhibition of metastasis and survival of cancer Stem Cells
The invention could be used as a companion diagnostic to help healthcare professionals determine the best therapeutic option for melanoma patients. Doctors could know in advance which patients would probably develop metastasis. As well as, they would have an alternative treatment for those patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib.